Business Wire

EnChroma Launches International Color Blindness Awareness Month

15.9.2022 05:02:00 EEST | Business Wire | Press release

Share

EnChroma, Inc. – creators of glasses for color blindness – today announced the launch of International Color Blindness Awareness Month. During the entire month of September, EnChroma and over 50 museums, libraries, school districts, state and federal parks, universities, tourism agencies, and Lions and Kiwanis Clubs will make social media posts and publish other communications designed to educate their members, students, communities and/or followers about Color Vision Deficiency (CVD, or “color blindness”).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220901005741/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Image courtesy of EnChroma @enchroma

“We are pleased that so many esteemed institutions have joined EnChroma to promote International Color Blindness Month to educate the world about the impact color vision deficiency has on people at work, in school, and in fully appreciating art or the colors of nature,” said Erik Ritchie, CEO of EnChroma. “More awareness will result in fewer daily frustrations for color blind people and more accessibility.”

Color blindness affects one in 12 men (8%) and one in 200 women (.5%); 350 million people worldwide. While people with normal color vision see over one million shades of color, those with Color Vision Deficiency only see an estimated 10% of hues and shades. Common color confusions include green and yellow, gray and pink, purple and blue, and red can appear brown. Click here for images depicting color blindness.

The 50+ organizations supporting International Color Blindness Month include:

• Georgia O'Keeffe Museum, NM

• Boston University, MA

• Faber-Castell, Germany

• North Carolina State University, NC

• Birmingham Museum of Art, AL

• Anythink Libraries, CO

• Museum of Contemporary Art Denver

• Penn State University, Forensic Science Dept., PA

• J.N. "Ding" Darling National Wildlife Refuge, FL

• Fondazione Paolina Brugnatelli, Milan, Italy

• Lions Club, District L, NC

• Clinton-Macomb Public Library, MI

• Cantigny Park, IL

• Nelson-Atkins Museum of Art, MO

• School District of New London, WI

• Nahant Public Library, MA

• Johnson County Public Library, IN

• Dallas Museum of Art, TX

• Lions Club, Adams, MN

• RISD, Museum of Art, Rhode Island School of Design, RI

• St. Johns County Public Libraries, FL

• Alfred University, NY

• Museum of Fine Arts, St. Petersburg, FL

• i.d.e.a. Museum, AZ

• Central High School (D301), IL

• Kiwanis Club of Findlay, OH

• Shelburne Museum, VT

• Glen Ridge Public Library, NJ

• Lions Club, District I, NC

• Downers Grove Public Library, IL

• National Museum of Wildlife Art, WY

• Motlow State Community College, TN

• Mulvane Art Museum, KS

• Lions Club, District S, NC

• Albrecht-Kemper Museum of Art, MO

• Spiva Center for the Arts, MO

• Eye See Color Project, FL

• Helsingin Optiikka Oy, Finland

• Plainfield Area Public Library, IN

• Evansville Vanderburgh Public Library, IN

•Technology Aids for the Blind & Visually Impaired, NC

 

• Lions Club, District O, NC

• Unique Optiek BV, The Netherlands

• Lions Club, District N, NC

• Carolyn Campagna Kleefeld Contemporary Art Museum, CA

• Jonathan Jones Color Blind Fund, AZ

EnChroma encourages other organizations and individuals to promote color blindness awareness anytime in September by posting to social media, websites and other forums using any of the templates located here, and/or images showing the color blind view of various settings here.

EnChroma Color Accessibility Program

EnChroma continues to lead in advocating for “color accessibility” through its EnChroma Color Accessibility Program, in which over 150 organizations participate. The program helps public venues such as schools, state parks, libraries, museums, tourism bureaus, resorts and other organizations loan EnChroma glasses to color blind students and guests to help make schoolwork that involves color, colorful exhibits, attractions and/or experiences accessible to the color blind.

Through the program, EnChroma donates a pair of glasses to an organization for every pair it purchases. Materials to educate teachers, parents, employers and others about color blindness, and how to support color blind students, children, employees and visitors, are also provided. EnChroma encourages schools to easily and quickly test all students for color blindness using its free online color vision test. Email accessibility@enchroma.com to learn about the program.

EnChroma’s patented lens technology helps people with red-green color blindness see an expanded range of colors and see them more vibrantly, clearly and distinctly. Studies by world-renowned color vision scientists at the University of California, Davis and France’s INSERM Stem Cell and Brain Research Institute, and the University of the Incarnate Word, have demonstrated the effectiveness of EnChroma glasses.

Story Assets for Media

Visit our Media Kit to download user videos, photos of EnChroma glasses and b-roll.

About EnChroma

Based in Berkeley, Calif., EnChroma produces leading-edge eyewear for color blindness and low vision, and other solutions for color vision, sold online and through Authorized Retailers worldwide. Invented in 2010, EnChroma’s patented eyewear combines the latest in color perception, neuroscience and lens innovation to improve the lives of people with color vision deficiency around the world. EnChroma received an SBIR grant from the National Institutes of Health (NIH). It earned the 2016 Tibbetts Award from the U.S. Small Business Administration in recognition of the firm’s innovative impact on the human experience through technology, and the 2020 Innovation Award in Life Sciences from the Bay Area’s East Bay Economic Development Alliance. Visit enchroma.com to learn more.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact
Kent Streeb
Vice President of Communications and Partnerships
P: 530.908.9225
kent@enchroma.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 16:00:00 EEST | Press release

Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around

HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 15:00:00 EEST | Press release

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate

Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 15:00:00 EEST | Press release

The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 500 million AGR uranium pellets and 222,000 AGR grids – which is equivalent to burning over 685 tonnes of coal, avoiding the emission of nearly 3 billion tonnes of CO2. Sp

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye